Boundless Bio Makes $100M IPO Debut on Nasdaq by Mark Eisenberg 28.03.2024 Precision oncology company Boundless Bio is set to go public with a $100 million IPO on the Nasdaq, trading under ...
Sosei Heptares: Strategic Wins Propel Growth by Mark Eisenberg 13.02.2024 Sosei Group Corporation announces operational activities and consolidated results, including significant investment, marketing approval, and partnerships. Despite revenue decrease, the ...
NRx Pharmaceuticals: $5M Boost for NRX-101 Drug by Mark Eisenberg 12.02.2024 NRx Pharmaceuticals receives a $5 million milestone payment for the development of its drug candidate NRX-101, supporting its progress through ...
Gilead Acquires CymaBay: Liver Cure Leap? by Mark Eisenberg 12.02.2024 Gilead Sciences acquires CymaBay Therapeutics for $4.3 billion to expand its liver disease portfolio, including access to potential treatment for ...
Tonix Pharma’s Potential PTSD Cure: A Game-Changer? by Mark Eisenberg 12.02.2024 Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
Investing in Psychedelics for Net Zero Trauma by Mark Eisenberg 11.01.2024 Investors are turning to psychedelics as a game-changer for mental health. The recent $100 million financing for Lykos Therapeutics shows ...